Approved yesterday by the FDA, Trelegy Ellipta is the first ever daily single-inhaler to combine a triple therapy for COPD, and could ... as the first Advair generic looks to be just around ...
Teva has launched new digital inhaler ... generic version of GlaxoSmithKline’s blockbuster inhaler Advair (fluticasone+salmeterol). The competition for the product approved in asthma and COPD ...
Qnovia, Inc., a pharmaceutical company developing inhaled therapeutics across a variety of indication areas leveraging its proprietary inhaled drug delivery platform, the RespiRxtm, today announced ...
For patients with chronic obstructive pulmonary disease (COPD), budesonide-glycopyrrolate-formoterol does not improve ...
News Medical on MSN3d
Study finds no clinical advantage of budesonide inhaler over fluticasone in COPDA study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...
They provided evidence to guide treatment decisions for COPD patients. Study: Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease ...
In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...
a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched pairs of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback